title: Tau Positron Emission Tomography Imaging.
abstract: Alzheimer's disease (AD) is a chronic neurodegenerative disorder and the most common cause of dementia among the elderly population. The good correlation between the density and neocortical spread of neurofibrillary tangles (NFTs) and the severity of cognitive impairment offers an opportunity to use a noninvasive imaging technique such as positron emission tomography (PET) for early diagnosis and staging of the disease. PET imaging of NFTs holds promise not only as a diagnostic tool but also because it may enable the development of disease-modifying therapeutics for AD. In this review, we focus on the structural diversity of tau PET tracers, the challenges related to identifying high-affinity and highly selective NFT ligands, and recent progress in the clinical development of tau PET radioligands.
authors.affiliation: Janssen Research and Development, Neuroscience Biomarkers, San Diego, California 92121.
authors.forename: Hartmuth C
authors.initials: HC
authors.lastname: Kolb
authors.affiliation: Janssen Research and Development, Discovery Sciences, Janssen-Cilag S.A., 45007 Toledo, Spain.
authors.forename: José Ignacio
authors.initials: JI
authors.lastname: Andrés
mesh_terms: D000544:Alzheimer Disease / Q000000981:diagnostic imaging* / Q000378:metabolism*; D000818:Animals; D006801:Humans; D049268:Positron-Emission Tomography / Q000379:methods*; D019275:Radiopharmaceuticals / Q000378:metabolism*; D016875:tau Proteins / Q000378:metabolism*
chemical_list: D019275:Radiopharmaceuticals; D016875:tau Proteins